Melanoma Clinical Trials
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265).
MASTERKEY‐265 is a phase 1b/3 clinical trial that will evaluate the safety and efficacy of the investigational combination of these two different immunotherapies (talimogene laherparepvec and pembrolizumab) in patients with advanced melanoma. Advanced melanoma has usually spread to other parts of the skin, regional or distant lymph nodes, lungs, or liver. In addition, the advanced disease cannot be cured with surgery alone.
MAVIS: A Multi-center, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patient with a High Risk of Recurrence
The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma in patients who have previously undergone resection surgery.
Schedule a Consultation Today!
Your health is important, and we welcome the opportunity to help you heal.
To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or use our interactive Online Appointment Request Form.